Dostarlimab (Jemperli) – NCPE Rapid Review Recommends Full HTA for Endometrial Cancer (ncpe.ie)

• Rapid review completed; full HTA recommended
• Indication: advanced/recurrent endometrial cancer (MMRp/MSS)
• HSE reimbursement decision pending under Irish drug pricing law

"Ireland's National Centre for Pharmacoeconomics (NCPE) completed a rapid review of dostarlimab (Jemperli) combined with carboplatin and paclitaxel for first-line treatment of adult patients with advanced/recurrent endometrial cancer (MMRp/MSS subgroup). The review recommends a full health technology assessment (HTA) to evaluate clinical and cost-effectiveness versus current standard of care. The HSE will consider the NCPE assessment in its reimbursement decision under the Health (Pricing and Supply of Medical Goods) Act 2013."